Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Health Canada Approves Biocon and Mylan's Ogivri™, the First Trastuzumab Biosimilar

Posted On: 2019-05-24 10:40:10

Biocon Ltd. and Mylan N.V. has announced that Health Canada has approved Mylan's Ogivri™ (trastuzumab), a biosimilar to Herceptin®1 (trastuzumab) co-developed with Biocon, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).

Ogivri is the first trastuzumab biosimilar approved in Canada and the second biosimilar from Biocon and Mylan's joint portfolio approved in the market. Mylan plans to launch the product this quarter and anticipates potentially being the first company to offer a trastuzumab biosimilar in Canada.

Dr Christiane Hamacher, CEO, Biocon Biologics said, "We are pleased to enable access to Ogivri, a high quality biosimilar trastuzumab co-developed and manufactured by Biocon as an affordable treatment option for HER2- positive breast and gastric cancer patients in Canada. The Health Canada approval granted to Ogivri, will pave the way for its commercialization by our partner Mylan. Thousands of patients in Europe, India and key emerging markets are benefitting from our biosimilar trastuzumab. Biocon Biologics is committed to address unmet patient needs through its high quality, affordable biologics, globally."

Mylan's Chief Commercial Officer Tony Mauro commented, "As a global leader in the development of complex products, including biosimilar medicines, we're pleased to reach this approval milestone for Ogivri and the opportunity to bring this important treatment option to market for Canadian patients with HER2-positive breast and gastric cancers. We look forward to continuing our reimbursement discussions with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Pan-Canadian Pharmaceutical Alliance (pCPA} to ensure that patients have access to Ogivri."

Approval by Health Canada was based on robust data from structural and functional characterization using multiple orthogonal techniques, nonclinical studies and pharmacokinetic evaluation in healthy subjects and patients and a safety, efficacy and immunogenicity study in relevant patient populations, which compared Ogivri to Herceptin. The data demonstrated that Ogivri is highly similar to Herceptin with no clinically meaningful differences in terms of efficacy, safety, purity and potency.

Biocon and Mylan's trastuzumab biosimilar is currently approved in more than 65 countries around the world, including the U.S.

Shares of BIOCON LTD. was last trading in BSE at Rs.510.7 as compared to the previous close of Rs. 519.6. The total number of shares traded during the day was 144554 in over 3535 trades.

The stock hit an intraday high of Rs. 526.95 and intraday low of 509.05. The net turnover during the day was Rs. 74890459.

1 Herceptin® is a product of Hoffmann-La Roche Ltd.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Persistent Systems arm to acquire Youperience GmbH

ICRA revises ratings of Sasan Power Ltd

IFCI update on Corporate Business Plan

Jump Networks Launches Rural Organic Farming Initiative Using TORUS

Asian Granito India Ltd inaugurates new showroom in Himmatnagar

Jubilant Life Sciences Ltd issues CPs of Rs. 40 crore

Prism Johnson Ltd board to announce Q1 results on July 30, 2019

NTPC Wins 40 MW Solar Capacities In UPNEDA'S 500 MW Tender

DCW Ltd board to consider preferential issue for Rs. 80 crores

Endurance Technologies Ltd board to approve Q1 results on Aug 8, 2019

Godrej Properties Ltd board to consider QIP on June 28, 2019

Transpek Industry Ltd to restart operations at Ekalbara factory

Panorama Studios International and PVR Pictures collaborate to distribute films in India

SpiceJet introduces Riyadh as its 10th international destination

TCS' Jile™ makes its debut in the Gartner 2019 Magic Quadrant for Enterprise Agile Planning Tools

Infosys named a Leader among API Strategy and Delivery Service Providers in 2019 Report

Mideast Integrated Steels Ltd announces resignation of Mr Dipak Chatterjee

Nestle India Introduces MAGGI Fusian Noodles range

Dr. Reddy's Laboratories announces the launch of Tobramycin Inhalation Solution, USP in the U.S. Market

Indag Rubber Ltd board to consider Q1 results on July 23, 2019

Shriram Capital Ltd updates on potential exit of Piramal and TPG

Finolex Cables Ltd board to approve Q1 results on Aug 14, 2019

Wisec Global Ltd announces resignation of independent director

Kalpataru Power Transmission Ltd calls for board meeting on July 2, 2019

IndusInd Bank inaugurates a branch in Jewar, Uttar Pradesh

Subex joins Global Leaders' Forum Communications Blockchain Network

Genus Paper & Boards Ltd appoints Mr. Pradeep Narain Tandon as additional director

JSW Steel Ltd board to announce Q1 results on July 26, 2019

Nucleus Software's latest version of FinnOne Neo to help lenders accelerate their path to digital revenues

Alembic Pharmaceuticals receives USFDA Approval for Oseltamivir Phosphate Capsules USP

Court Grants Non Bailable Arrest Warrants of Kislay Panday & Ram Mani Panday

Alankit spearheads large-scale Student ID card project - A smart initiative by the e-Governance leader

Mahindra World City, Jaipur inaugurates 'Digital Literacy Centre' in Laliya-Ka-Bas Village

TAAL Enterprises Ltd Q4 PAT rises to Rs. 6.43 crores

Quess Corp Ltd to consider raising of Rs. 51 crores

Andhra Bank board approves proposal to raise Rs. 2000 crore

Welspun Corp Ltd fixes July 5, 2019 as record date for buy back

Quess Corp arm bags work order from Amazon

TTK Prestige Ltd board to announce Q1 results on August 12, 2019

IFCI to sell its 2.44% stake in NSE

Master Trust Ltd Board to consider Sub-division of equity shares

Eris Lifesciences Ltd Board to consider Buyback of equity shares

RITES announces 1:4 Bonus Share Issue

L&T announces offer for sale of shares of L&T Technology Services Ltd at Rs. 1650

Offer for Sale of Shares of SBI Life Insurance Company Ltd announced by Promoter

Zensar Technologies Ltd board to approve Q1 results on Aug 6, 2019

Emami Group Promoters divest 10% stake for INR 1230 cr in Emami Limited

Ind-Ra affirms long term rating of HEG Ltd

TCS hikes Stake in JV with Mitsubishi Corporation

Som Distilleries & Breweries Ltd calls for board meeting on July 3, 2019







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019